Showing 1 - 3 results of 3 for search 'Peyman Hadji', query time: 0.13s Refine Results
  1. 1
    The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype

    The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype by Philipp Ziegler, Andreas D. Hartkopf, Markus Wallwiener, Lothar Häberle, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Volkmar Müller, Laura L. Michel, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Hanna Huebner, Sabrina Uhrig, Lena A. Wurmthaler, Carolin C. Hack, Christoph Mundhenke, Christian Kurbacher, Peter A. Fasching, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss, Chloë Goossens

    Published 2024-10-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG

    Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO,... by Peyman Hadji, Matty Aapro, Nasser Al-Dagri, Majed Alokail, Emmanuel Biver, Jean-Jacques Body, Maria Luisa Brandi, Janet Brown, Cyrille Confavreux, Bernard Cortet, Matthew Drake, Peter Ebeling, Erik Fink Eriksen, Ghada El-Hajj Fuleihan, Theresa A. Guise, Nick C. Harvey, Andreas Kurth, Bente Langdahl, Willem Lems, Radmila Matijevic, Eugene McCloskey, Rossella Nappi, Santiago Palacios, Georg Pfeiler, Jean-Yves Reginster, René Rizzoli, Daniele Santini, Sansin Tuzun, Catherine Van Poznak, Tobias De Villiers, M. Carola Zillikens, Robert Coleman

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer

    Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer by Christina B. Walter, Andreas D. Hartkopf, Alexander Hein, Peter A. Fasching, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Laura L. Michel, Erik Belleville, Hanna Huebner, Sabrina Uhrig, Chloë Goossens, Pauline Wimberger, Carsten Hielscher, Julia Meyer, Christoph Mundhenke, Christian Kurbacher, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Tanja N. Fehm, Carlo Fremd

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: